The GIMEMA LAL2317 protocol investigated the frontline chemotherapy-blinatumomab combination in adult Philadelphia- CD19+ B-lineage acute lymphoblastic leukemia (Ph- B-ALL) to improve minimal residual disease (MRD) response and clinical outcome. Two cycles of intravenous blinatumomab were administered after chemotherapy cycles 3 and 6. The primary endpoint was the rate of molecular MRD negativity following blinatumomab 1. One hundred and forty-nine patients were enrolled (median age 41 …